Progentec Diagnostics
Progentec: Pioneering next-gen diagnostics and digital biomarkers for enhanced autoimmune disease care.
Founded
2015Progentec: Pioneering next-gen diagnostics and digital biomarkers for enhanced autoimmune disease care.
Progentec Diagnostics, founded with the mission to revolutionize autoimmune disease care, focuses on developing next-generation diagnostics and digital biomarkers. The company aims to transform the management of autoimmune diseases such as lupus and multiple sclerosis through innovative blood-based tests and digital health tools. Their flagship products include the aiSLE® DX Flare Risk Index and aiSLE® DX Disease Activity Index, which are available through Mayo Clinic Laboratories. Progentec’s market focus is on providing advanced diagnostic solutions to healthcare providers and patients for proactive disease management.
Notable affiliations include partnerships with Mayo Clinic Laboratories, enhancing the credibility and reach of their diagnostic tests. Progentec has achieved significant milestones, including the successful launch of their aiSLE™ MGMT platform, which integrates proteomics and digital health insights for better disease management. The company’s impact is evident in its contribution to improving patient outcomes and enabling more personalized care for those with autoimmune conditions. Through their pioneering work, Progentec is setting new standards in the diagnostics industry.
Companies similar to Progentec Diagnostics include Exagen, Probius, Proactive Diagnostics and Proxim Diagnostics.
Progentec Diagnostics was founded in 2015.
Progentec Diagnostics' headquarters is located in Oklahoma City, OK, US.
Progentec Diagnostics' most recent funding round was for $5M (USD) in January 2020.
As of Jan 9, 2020, Progentec Diagnostics has raised a total of $6.3M (USD).
Progentec Diagnostics has 14 employees as of Feb 5, 2024.
Proactive Diagnostics
pro-dx.com
